School of Medicine and Surgery, University of Milan-Bicocca, 20900 Monza, Italy.
Experimental Neurology Unit, University of Milano-Bicocca, 20900 Monza, Italy.
Molecules. 2019 Jul 9;24(13):2500. doi: 10.3390/molecules24132500.
Multiple myeloma (MM) belongs to hematological cancers and its incidence is increasing worldwide. Despite recent advances in its therapy, MM still causes many deaths every year. In fact, current therapies sometimes fail and are associated with severe adverse effects, including neurotoxicity. As a part of our ongoing efforts to discover new potential therapies against MM, we prepared extracts obtained by a microwave-assisted solvent extraction and investigate their activity by in vitro assays on the RPMI-8226 cell line. The bioguided fractionation of the crude ethanolic extract allowed the identification of HsFC as the most effective extract. We assessed cell viability (MTT and Tripan blue test), cell migration (Boyden chamber assay), and neurotoxicity (DRG neurotoxicity assay). The promising results prompted us to further fractionate HsFC and we obtained two molecules effective against RPMI-8226 cells without neurotoxic effects at their active concentrations. Moreover, both compounds are able to significantly reduce cell migration.
多发性骨髓瘤（MM）属于血液系统恶性肿瘤，其发病率在全球范围内呈上升趋势。尽管近年来在治疗方面取得了进展，但多发性骨髓瘤每年仍导致许多人死亡。事实上，目前的治疗方法有时会失败，并伴有严重的不良反应，包括神经毒性。作为我们正在进行的努力的一部分，旨在发现针对 MM 的新的潜在治疗方法，我们准备了通过微波辅助溶剂提取获得的提取物，并通过 RPMI-8226 细胞系的体外测定来研究它们的活性。粗醇提取物的生物导向分离允许鉴定 HsFC 是最有效的提取物。我们评估了细胞活力（MTT 和台盼蓝试验）、细胞迁移（Boyden 室测定）和神经毒性（DRG 神经毒性测定）。有前途的结果促使我们进一步对 HsFC 进行分段，我们得到了两种对 RPMI-8226 细胞有效的分子，在其有效浓度下没有神经毒性作用。此外，这两种化合物都能够显著减少细胞迁移。
